SBP Group profit attributable to owners rises 1.4% to RMB 3.43 billion in 1H FY26; revenue climbs 10.6% to RMB 19.44 billion

• Sino Biopharmaceutical posted 1H 2026 revenue of RMB 19.44 billion, up 10.6% year on year.
• Profit attributable to owners of the parent under HKFRS edged up 1.4% to RMB 3.43 billion.
• Underlying profit attributable to owners of the parent, a non-HKFRS measure, rose 8.1% to RMB 3.34 billion.
• Innovative drugs and out-licensing sales climbed 44.3% to RMB 8.79 billion, lifting their revenue share by 10.5 percentage points to 45.2%.
• The board declared an interim dividend of HK$0.07 per share; management highlighted global licensing deals with Sanofi and AstraZeneca.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12289829), on August 19, 2026, and is solely responsible for the information contained therein.